Bone Biologics Co. (NASDAQ:BBLG) Sees Large Decline in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 58,200 shares, a decline of 19.3% from the October 31st total of 72,100 shares. Currently, 10.9% of the shares of the stock are sold short. Based on an average daily volume of 3,010,000 shares, the days-to-cover ratio is currently 0.0 days.

Bone Biologics Stock Down 3.2 %

Shares of BBLG traded down $0.04 during trading hours on Friday, hitting $1.22. 99,011 shares of the stock were exchanged, compared to its average volume of 1,471,036. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $10.56. The stock’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.54.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.